Is AbbVie Stock Too Reliant On Skyrizi?

AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.

A Third Of Revenue Comes From SKYRIZI

SKYRIZI, AbbVie’s psoriasis and Crohn’s disease biologic, sold $5.5 billion in Q2 2026, up 24% on an operational basis, inside total net revenues of nearly $17 billion that grew 10.2% as reported. Management’s full-year 2026 forecast puts SKYRIZI at about $21.7 billion against roughly $67.6 billion of total net revenues. That is 32% of AbbVie in one molecule.

The franchise earns its reputation. In psoriasis, management says SKYRIZI leads market share in more than 30 countries and takes new and switching patients at four times the rate of any other biologic or oral treatment in the US. That strength is what makes the number uncomfortable.

And AbbVie Has Seen How That Ends

The company already ran this experiment. HUMIRA global sales were $756 million in Q2 2026, down 36.1% on an operational basis, which management attributes to biosimilar competition and calls in line with expectations. SKYRIZI now sells over seven times what HUMIRA does in a quarter.

The calm language is the point. An exclusivity loss is not a stumble management can fix. It arrives on a schedule, and SKYRIZI’s patents already have a date on them.

You Have Years Before The Patent Expires

Management says SKYRIZI’s composition of matter patent runs to 2033, later US patents, granted and still in process, extend into the mid-2030s, and regulatory data protection holds until 2031. It also says it has seen no degradation in prescription trends since a competing oral treatment launched earlier in 2026. These expectations reflect management’s current internal tracking and forward-looking guidance.

But What Comes After SKYRIZI Is Still In Trials

The investigational assets and label expansions meant to broaden AbbVie’s post-2030 base have yet to reach the market. Sixteen-week readouts for lutikizumab and RINVOQ in hidradenitis suppurativa are due before the end of 2026. A Phase 2b trial combining SKYRIZI with a novel antibody in Crohn’s disease and ulcerative colitis is only in start-up. The Apogee Therapeutics deal, which adds dermatology and respiratory assets, was, as of the Q2 2026 earnings call, expected to close in Q3 2026, and its $0.14 of anticipated dilution more than offsets the $0.10 AbbVie added to its full-year 2026 adjusted earnings outlook.

The one launch that is close makes the problem worse. A US decision on SKYRIZI subcutaneous induction in Crohn’s disease is due in the fall of 2026, a European application was submitted in August 2026, and management expects a meaningful acceleration for SKYRIZI from it, though the company says that will probably start showing early in 2027. Every win here deepens the same dependency.

So how worried should you be? Worried enough to size the position on purpose. AbbVie’s largest product continues to outpace the overall business while the pipeline meant to diversify it is still generating zero revenue, and options markets are pricing business as usual: implied volatility sits at 25, the 44th percentile of its trailing one-year range, reflecting an ordinary volatility environment rather than any elevated expectation of near-term turbulence. Watch whether RINVOQ, the neuroscience portfolio and the Apogee assets grow the non-SKYRIZI base faster than SKYRIZI grows.

Can You Diversify Inside One Stock?

You cannot, and owning more of a good stock does not fix it. The Trefis High Quality Portfolio spreads that exposure across a rules-based group of businesses instead of one franchise’s patent calendar. That portfolio has a track record of outpacing the three major indices.